Symbols / TLSA Stock $1.27 +7.63% Tiziana Life Sciences Ltd
TLSA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteTiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Ratings
Current target
$1.27
Low
$9.01
High
$9.01
Mean
$9.01
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2022-06-13 | init | ThinkEquity | — → Buy | $4 |
- Nasal antibody trial in progressive MS sees 64% with less fatigue - Stock Titan ue, 19 May 2026 07
- While insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownership - Yahoo Finance Mon, 09 Feb 2026 08
- Why Is TLSA Stock Rising Today? - Stocktwits hu, 21 May 2026 16
- Tiziana Life Sciences Announces $8 Million Registered Direct Offering of Ordinary Shares to Support Clinical Trials - Quiver Quantitative Fri, 16 Jan 2026 08
- A J.P. Morgan analyst sees 60% downside to Tesla stock—and he may be too optimistic - Fortune ue, 07 Apr 2026 07
- Tiziana Life Sciences to Showcase Intranasal Foralumab Progress at Jefferies Healthcare Conference - The Globe and Mail Fri, 29 May 2026 11
- Biotech Tiziana to brief investors on clinical updates at Jefferies event - Stock Titan hu, 28 May 2026 11
- Tiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment Update - Yahoo Finance hu, 21 May 2026 07
- Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative Mon, 15 Dec 2025 08
- CEO backs $17.6M Tiziana raise to fund key na-SPMS and MSA trials - Stock Titan Fri, 16 Jan 2026 08
- TSLA: Should You 'Buy' or 'Sell' Tesla Stock in 2026? - Yahoo Finance Fri, 02 Jan 2026 08
- Tiziana leaders invest in $8.8M raise to finish Phase 2 na-SPMS, MSA trials - Stock Titan Fri, 16 Jan 2026 08
- Nasal antibody for multiple sclerosis fills Phase 2 trial, results late Q3 2026 - Stock Titan hu, 21 May 2026 07
- Tiziana Life Sciences (TLSA) COO discloses Form 3 share and option holdings - Stock Titan Fri, 22 May 2026 07
- Experimental nasal MS antibody steadies disability in small study - Stock Titan ue, 20 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
—
|
| Gross Profit |
|
—
|
—
|
—
|
—
|
| Operating Expense |
|
21.13
+33.80%
|
15.79
-12.18%
|
17.98
+23.30%
|
14.59
|
| Research And Development |
|
10.28
+96.58%
|
5.23
-35.55%
|
8.11
-37.38%
|
12.96
|
| Selling General And Administration |
|
—
|
—
|
0.00
|
0.00
|
| General And Administrative Expense |
|
—
|
—
|
—
|
—
|
| Salaries And Wages |
|
—
|
—
|
0.00
|
0.00
|
| Other Operating Expenses |
|
10.85
+2.73%
|
10.56
+7.03%
|
9.87
+505.21%
|
1.63
|
| Total Expenses |
|
21.13
+33.80%
|
15.79
-12.18%
|
17.98
+23.30%
|
14.59
|
| Operating Income |
|
-21.13
-33.80%
|
-15.79
+12.18%
|
-17.98
-23.30%
|
-14.59
|
| Total Operating Income As Reported |
|
-21.13
-33.80%
|
-15.79
+12.18%
|
-17.98
-23.30%
|
-14.59
|
| EBITDA |
|
-18.18
-9.41%
|
-16.62
+3.03%
|
-17.14
-11.94%
|
-15.31
|
| Normalized EBITDA |
|
-20.88
-40.54%
|
-14.86
+11.22%
|
-16.73
-15.89%
|
-14.44
|
| Reconciled Depreciation |
|
0.23
+88.71%
|
0.12
+29.17%
|
0.10
+88.24%
|
0.05
|
| EBIT |
|
-18.41
-9.99%
|
-16.74
+2.86%
|
-17.23
-12.19%
|
-15.36
|
| Total Unusual Items |
|
2.70
+253.41%
|
-1.76
-337.81%
|
-0.40
+53.74%
|
-0.87
|
| Total Unusual Items Excluding Goodwill |
|
2.70
+253.41%
|
-1.76
-337.81%
|
-0.40
+53.74%
|
-0.87
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Write Off |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-18.43
-55.37%
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
|
| Pretax Income |
|
-18.43
-10.06%
|
-16.75
+2.88%
|
-17.24
-11.98%
|
-15.40
|
| Net Non Operating Interest Income Expense |
|
0.00
-99.88%
|
0.81
-29.37%
|
1.14
+19166.67%
|
-0.01
|
| Interest Expense Non Operating |
|
0.02
+200.00%
|
0.01
-40.00%
|
0.01
-73.68%
|
0.04
|
| Net Interest Income |
|
0.00
-99.88%
|
0.81
-29.37%
|
1.14
+19166.67%
|
-0.01
|
| Interest Expense |
|
0.02
+200.00%
|
0.01
-40.00%
|
0.01
-73.68%
|
0.04
|
| Interest Income Non Operating |
|
0.02
-97.67%
|
0.81
-29.46%
|
1.15
+3506.25%
|
0.03
|
| Interest Income |
|
0.02
-97.67%
|
0.81
-29.46%
|
1.15
+3506.25%
|
0.03
|
| Other Income Expense |
|
2.70
+253.41%
|
-1.76
-337.81%
|
-0.40
+50.00%
|
-0.80
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
0.07
|
| Gain On Sale Of Security |
|
2.70
+253.41%
|
-1.76
-337.81%
|
-0.40
+53.74%
|
-0.87
|
| Tax Provision |
|
0.00
+100.00%
|
-4.88
-1187.53%
|
0.45
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+38.85%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.51
-507.92%
|
-0.08
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-18.43
-55.37%
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
|
| Net Income From Continuing Operation Net Minority Interest |
|
-18.43
-55.37%
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
|
| Net Income From Continuing And Discontinued Operation |
|
-18.43
-55.37%
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
|
| Net Income Continuous Operations |
|
-18.43
-55.37%
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
|
| Normalized Income |
|
-21.13
-99.04%
|
-10.62
+38.89%
|
-17.37
-19.59%
|
-14.53
|
| Net Income Common Stockholders |
|
-18.43
-55.37%
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
|
| Diluted EPS |
|
-0.16
-45.45%
|
-0.11
+35.29%
|
-0.17
-13.33%
|
-0.15
|
| Basic EPS |
|
-0.16
-45.45%
|
-0.11
+35.29%
|
-0.17
-13.33%
|
-0.15
|
| Basic Average Shares |
|
118.28
+10.88%
|
106.67
+4.10%
|
102.47
+0.93%
|
101.53
|
| Diluted Average Shares |
|
118.28
+10.88%
|
106.67
+4.10%
|
102.47
+0.93%
|
101.53
|
| Diluted NI Availto Com Stockholders |
|
-18.43
-55.37%
|
-11.86
+32.94%
|
-17.69
-14.90%
|
-15.40
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets |
|
11.28
-7.39%
|
12.18
-53.98%
|
26.48
|
| Current Assets |
|
7.51
+2.33%
|
7.34
-69.78%
|
24.28
|
| Cash Cash Equivalents And Short Term Investments |
|
3.72
+214.79%
|
1.18
-93.47%
|
18.12
|
| Cash And Cash Equivalents |
|
3.72
+214.79%
|
1.18
-93.47%
|
18.12
|
| Receivables |
|
3.69
-39.00%
|
6.05
+1.04%
|
5.99
|
| Other Receivables |
|
0.05
-56.20%
|
0.12
-6.92%
|
0.13
|
| Taxes Receivable |
|
0.03
-99.16%
|
3.79
-10.67%
|
4.25
|
| Prepaid Assets |
|
0.09
-9.80%
|
0.10
-40.00%
|
0.17
|
| Hedging Assets Current |
|
—
|
—
|
—
|
| Total Non Current Assets |
|
3.78
-22.10%
|
4.85
+120.82%
|
2.19
|
| Net PPE |
|
0.19
-36.18%
|
0.29
-24.68%
|
0.39
|
| Gross PPE |
|
0.19
-36.18%
|
0.29
-24.68%
|
0.39
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
| Other Properties |
|
0.19
-36.18%
|
0.29
-24.68%
|
0.39
|
| Goodwill And Other Intangible Assets |
|
—
|
0.00
|
0.00
|
| Investments And Advances |
|
3.59
-21.19%
|
4.55
+152.16%
|
1.81
|
| Long Term Equity Investment |
|
3.59
-21.19%
|
4.55
+152.16%
|
1.81
|
| Non Current Accounts Receivable |
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
7.35
+10.53%
|
6.65
-3.74%
|
6.91
|
| Current Liabilities |
|
7.35
+12.37%
|
6.54
-1.86%
|
6.66
|
| Payables And Accrued Expenses |
|
7.23
+13.20%
|
6.39
-2.22%
|
6.53
|
| Payables |
|
5.58
+34.88%
|
4.14
-16.63%
|
4.96
|
| Accounts Payable |
|
5.58
+34.88%
|
4.14
-16.63%
|
4.96
|
| Current Accrued Expenses |
|
1.65
-26.67%
|
2.25
+43.31%
|
1.57
|
| Current Debt And Capital Lease Obligation |
|
0.11
-23.19%
|
0.14
+13.11%
|
0.12
|
| Current Capital Lease Obligation |
|
0.11
-23.19%
|
0.14
+13.11%
|
0.12
|
| Current Deferred Liabilities |
|
0.00
|
—
|
—
|
| Current Deferred Revenue |
|
0.00
|
—
|
—
|
| Other Current Liabilities |
|
0.01
-14.29%
|
0.01
+55.56%
|
0.01
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.11
-55.14%
|
0.24
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.11
-55.14%
|
0.24
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.11
-55.14%
|
0.24
|
| Stockholders Equity |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Common Stock Equity |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Capital Stock |
|
0.11
+7.77%
|
0.10
+0.98%
|
0.10
|
| Common Stock |
|
0.11
+7.77%
|
0.10
+0.98%
|
0.10
|
| Share Issued |
|
111.46
+8.12%
|
103.09
+0.80%
|
102.27
|
| Ordinary Shares Number |
|
111.46
+9.80%
|
101.51
+0.92%
|
100.59
|
| Treasury Shares Number |
|
0.00
-100.00%
|
1.57
-6.54%
|
1.68
|
| Additional Paid In Capital |
|
23.11
+40.10%
|
16.49
+5.75%
|
15.60
|
| Retained Earnings |
|
-144.83
-8.34%
|
-133.68
-14.98%
|
-116.26
|
| Gains Losses Not Affecting Retained Earnings |
|
116.99
-0.06%
|
117.06
+1.29%
|
115.57
|
| Treasury Stock |
|
0.00
-100.00%
|
1.57
+19.24%
|
1.32
|
| Other Equity Adjustments |
|
118.70
+0.00%
|
118.70
+0.00%
|
118.70
|
| Total Equity Gross Minority Interest |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Total Capitalization |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Working Capital |
|
0.16
-79.95%
|
0.80
-95.47%
|
17.62
|
| Invested Capital |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Total Debt |
|
0.11
-57.09%
|
0.25
-32.33%
|
0.36
|
| Capital Lease Obligations |
|
0.11
-57.09%
|
0.25
-32.33%
|
0.36
|
| Net Tangible Assets |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Tangible Book Value |
|
3.94
-28.90%
|
5.54
-71.71%
|
19.57
|
| Duefrom Related Parties Current |
|
3.61
+68.71%
|
2.14
+32.47%
|
1.61
|
| Dueto Related Parties Current |
|
—
|
—
|
0.00
|
| Foreign Currency Translation Adjustments |
|
-1.71
-4.34%
|
-1.64
+47.70%
|
-3.13
|
| Other Equity Interest |
|
8.56
+20.07%
|
7.13
+21.11%
|
5.89
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-12.85
-741.87%
|
-1.53
+90.28%
|
-15.70
+19.97%
|
-19.61
|
| Cash Flow From Continuing Operating Activities |
|
-12.85
-741.87%
|
-1.53
+90.28%
|
-15.70
+19.97%
|
-19.61
|
| Net Income From Continuing Operations |
|
-18.43
-10.06%
|
-16.75
+2.88%
|
-17.24
-11.98%
|
-15.40
|
| Depreciation Amortization Depletion |
|
0.23
+88.71%
|
0.12
+29.17%
|
0.10
+88.24%
|
0.05
|
| Depreciation |
|
0.23
+88.71%
|
0.12
+29.17%
|
0.10
+88.24%
|
0.05
|
| Depreciation And Amortization |
|
0.23
+88.71%
|
0.12
+29.17%
|
0.10
+88.24%
|
0.05
|
| Other Non Cash Items |
|
3.13
-11.09%
|
3.52
+662.56%
|
-0.62
|
—
|
| Stock Based Compensation |
|
1.14
-20.15%
|
1.43
-17.59%
|
1.73
+222.98%
|
-1.41
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
-0.15
-195.60%
|
0.16
-89.53%
|
1.52
+149.74%
|
-3.05
|
| Unrealized Gain Loss On Investment Securities |
|
-1.75
-199.55%
|
1.76
+337.81%
|
0.40
-53.74%
|
0.87
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.15
-196.20%
|
0.16
-89.60%
|
1.52
+147.72%
|
-3.18
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
|
0.00
|
| Change In Working Capital |
|
3.06
+654.71%
|
-0.55
+65.11%
|
-1.58
-35.91%
|
-1.16
|
| Change In Receivables |
|
-0.38
+74.27%
|
-1.47
+3.61%
|
-1.52
-31.61%
|
-1.16
|
| Change In Payables And Accrued Expense |
|
0.00
|
0.00
|
0.00
+100.00%
|
-1.35
|
| Change In Payable |
|
—
|
—
|
—
|
-1.35
|
| Change In Account Payable |
|
0.00
|
0.00
|
0.00
+100.00%
|
-1.35
|
| Change In Other Working Capital |
|
0.53
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
-0.31
-502.56%
|
0.08
-2.50%
|
0.08
-92.02%
|
1.00
|
| Change In Other Current Liabilities |
|
3.22
+284.27%
|
0.84
+707.97%
|
-0.14
-139.77%
|
0.35
|
| Investing Cash Flow |
|
3.04
+4385.92%
|
-0.07
+94.33%
|
-1.25
+68.64%
|
-4.00
|
| Cash Flow From Continuing Investing Activities |
|
3.04
+4385.92%
|
-0.07
+94.33%
|
-1.25
+68.64%
|
-4.00
|
| Net PPE Purchase And Sale |
|
-0.02
-10.53%
|
-0.02
|
0.00
|
0.00
|
| Purchase Of PPE |
|
-0.02
-10.53%
|
-0.02
|
0.00
|
0.00
|
| Capital Expenditure |
|
-0.02
-10.53%
|
-0.02
|
—
|
—
|
| Net Investment Purchase And Sale |
|
3.06
+5992.31%
|
-0.05
+95.85%
|
-1.25
+68.64%
|
-4.00
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-0.05
+95.85%
|
-1.25
+68.64%
|
-4.00
|
| Sale Of Investment |
|
3.06
|
0.00
|
0.00
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
10.01
+122.11%
|
4.50
+11162.50%
|
0.04
+172.73%
|
-0.06
|
| Cash Flow From Continuing Financing Activities |
|
10.01
+122.11%
|
4.50
+11162.50%
|
0.04
+172.73%
|
-0.06
|
| Net Issuance Payments Of Debt |
|
-0.20
-39.01%
|
-0.14
-18.49%
|
-0.12
-116.36%
|
-0.06
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
-0.20
-39.01%
|
-0.14
-18.49%
|
-0.12
-116.36%
|
-0.06
|
| Long Term Debt Payments |
|
-0.20
-39.01%
|
-0.14
-18.49%
|
-0.12
-116.36%
|
-0.06
|
| Net Long Term Debt Issuance |
|
-0.20
-39.01%
|
-0.14
-18.49%
|
-0.12
-116.36%
|
-0.06
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
10.06
+120.06%
|
4.57
+18945.83%
|
0.02
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.14
+90.67%
|
0.07
-44.44%
|
0.14
|
0.00
|
| Changes In Cash |
|
0.20
-93.05%
|
2.91
+117.20%
|
-16.91
+28.54%
|
-23.67
|
| Effect Of Exchange Rate Changes |
|
0.08
+122.89%
|
-0.37
-1210.71%
|
-0.03
+92.96%
|
-0.40
|
| Beginning Cash Position |
|
3.72
|
—
|
—
|
—
|
| End Cash Position |
|
4.01
+7.68%
|
3.72
+214.79%
|
1.18
-93.47%
|
18.12
|
| Free Cash Flow |
|
-12.87
-732.88%
|
-1.54
+90.16%
|
-15.70
+19.97%
|
-19.61
|
| Common Stock Issuance |
|
10.06
+120.06%
|
4.57
+18945.83%
|
0.02
|
0.00
|
| Issuance Of Capital Stock |
|
10.06
+120.06%
|
4.57
+18945.83%
|
0.02
|
0.00
|
| Taxes Refund Paid |
|
-0.07
-100.85%
|
8.78
|
0.00
-100.00%
|
0.49
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|